ArticleTrials2019

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Antonio Uccelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.